MOLECULAR BIOLOGICALLY DEVELOPED MEDICINES

Brand	Owner	Address	Description
ILTREX	MEDIGENE AG	Lochhamer Str. 11 Planegg-Martinsried 82152 Germany	MOLECULAR BIOLOGICALLY DEVELOPED MEDICINES, SERUMS, THERAPEUTIC PREPARATIONS FOR ANIMALS AND HUMANS FOR THE TREATMENT OF CARDIAC DISEASES, SKIN DISEASES, CANCER,DIABETES AND OBESITY; MOLECULAR BIOLOGICALLY DEVELOPED TEST KITS FOR CLINICAL AND MEDICAL LABORATORY USE, COMPRISED OF BIOCHEMICAL AND BIOTECHNOLOGICAL COMPONENTS FOR THE IDENTIFICATION, ANALYSIS AND VALIDATION OF TARGET GENES AND/OR THE IDENTIFICATION OF NEW PHARMACEUTICALLY ACTIVE COMPOUNDS FOR HUMAN MEDICAL AND VETERINARY MEDICAL DIAGNOSTIC AND THERAPY PURPOSES; AND MOLECULAR BIOLOGICALLY DEVELOPED DIAGNOSTIC PREPARATIONS FOR CLINICAL AND MEDICAL LABORATORY USE;
	Where the owner name is not linked, that owner no longer owns the brand

Technical Examples

Provided are novel processes for the efficient production of L-epi-2-inosose and epi-inositol which are useful either as various medicines or intermediates for the syntheses of various medicines. In the processes, inexpensive myo-inositol is used as a starting compound which is reacted with a gram-negative bacterium capable of converting myo-inositol into L-epi-2-inosose, and thereby producing L-epi-2-inosose by conversion of myo-inositol into L-epi-2-inosose. A biologically pure culture of Pseudomonas sp. AB 10215 strain is also provided which has a characteristic nature of being capable of converting myo-inositol into L-epi-2-inosose.